Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr53.50 SEK
Change Today +1.50 / 2.88%
Volume 338.3K
CEVI On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
As of 11:29 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

cellavision ab (CEVI) Snapshot

Open
kr52.00
Previous Close
kr52.00
Day High
kr55.00
Day Low
kr52.00
52 Week High
04/7/15 - kr56.00
52 Week Low
05/5/14 - kr20.50
Market Cap
1.3B
Average Volume 10 Days
144.8K
EPS TTM
kr1.32
Shares Outstanding
23.9M
EX-Date
05/7/15
P/E TM
40.5x
Dividend
kr1.00
Dividend Yield
0.93%
Current Stock Chart for CELLAVISION AB (CEVI)

Related News

No related news articles were found.

cellavision ab (CEVI) Related Businessweek News

No Related Businessweek News Found

cellavision ab (CEVI) Details

CellaVision AB (publ) develops and sells systems for routine analysis of blood and other body fluids in health care services sector. The company offers analyzers, supplementary software, and peripheral equipment for digital microscopy in the sub-field of hematology. Its products include CellaVision DM9600 and CellaVision DM1200, which automatically performs a preliminary differential count on peripheral blood or body fluid smears, as well as pre-classifies the white blood cells, pre-characterizes parts of the red morphology, and provides functionality for platelet estimation; DI-60, an automated blood analysis line; and CellaVision DM9600 Vet and CellaVision DM1200 Vet for blood analysis at veterinary laboratories. The company’s products comprise CellaVision Body Fluid Application for analyzing body fluids, including cerebrospinal, pleural and synovial fluids; CellaVision Remote Review Software that enables remote users to access analyzed slides, and reclassify cells and sign slides from another location; CellaVision Proficiency Software, a Web-based program for testing of blood and body fluid differentials; CellaVision Image Capture System that allows small labs performing differentials to streamline patient care; CellaVision Peripheral Blood Application for white blood cell differential, red blood cell characterization, and platelet estimation; CellaVision Advanced RBC Application, which performs pre-characterization of red blood cells; and CellAtlas mobile app. It also offers CellaVision Light Tower that provides visual and audible signals of the status of a CellaVision DM Analyzer; HemaPrep, an automated blood smearing instrument for blood cell analysis; and barcode label printer kit for reading and copying barcodes and generating barcode labels. The company sells its products to hospital and commercial laboratories in Europe, the Middle East, Africa, Americas, and the Asia Pacific. CellaVision AB (publ) was founded in 1994 and is headquartered in Lund, Sweden.

72 Employees
Last Reported Date: 04/10/15
Founded in 1994

cellavision ab (CEVI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cellavision ab (CEVI) Key Developments

Cellavision AB Reports Consolidated and Parent Company Earnings Results for the Full Year of 2014

CellaVision AB reported consolidated and parent company earnings results for the full year of 2014. For the year, on consolidated basis, the company reported net sales were SEK 216,916,000 against SEK 179,851,000 a year ago. Operating profit was SEK 42,813,000 against SEK 25,946,000 a year ago. Profit before tax was SEK 43,369,000 against SEK 24,690,000 a year ago. Net profit for the year was SEK 31,465,000 or SEK 1.32 diluted per share against SEK 18,932,000 or SEK 0.79 diluted per share a year ago. Cash flow from operating activities was SEK 39,784,000 against SEK 27,272,000 a year ago. Capitalization of development expenditure and technology acquisition was SEK 12,292,000 against SEK 10,196,000 a year ago. Purchases of property, plant and equipment was SEK 1,446,000 against SEK 1,597,000 a year ago. For the year, on parent company basis, net sales were SEK 207,041,000 against SEK 166,757,000 a year ago. Operating profit was SEK 43,214,000 against SEK 18,156,000 a year ago. Profit before tax was SEK 42,157,000 against SEK 2,151,000 a year ago. Net profit for the year was SEK 30,849,000 against loss of SEK 1,977,000 a year ago. Cash flow from operating activities was SEK 35,603,000 against SEK 23,177,000 a year ago. Capitalization of development expenditure and technology acquisitions was SEK 12,292,000 against SEK 10,196,000 a year ago. Purchases of property, plant and equipment was SEK 1,164,000 against SEK 662,000 a year ago.

CellaVision AB Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Proposes Dividend for the Year 2014

CellaVision AB announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s net sales increased by 12 % to SEK 72.5 million compared to SEK 64.9 million a year ago. Operating profit was SEK 16.8 million compared to SEK 16.3 million a year ago. Profit before tax was SEK 16.6 million against SEK 16.2 million a year ago. Earnings per share were SEK 0.49 compared to 0.54 a year ago. For the year, the company’s net sales increased by 21 % to SEK 216.9 million compared to SEK 179.9 million a year ago. Operating profit increased to SEK 42.8 million compared to SEK 25.9 million a year ago. Profit before tax increased to SEK 43.4 million compared to SEK 24.7 million a year ago. Earnings per share increased to SEK 1.32 compared to SEK 0.79 a year ago. The board of directors of the company proposed a dividend increase to SEK 1 per share for 2014 compared to SEK 0.50 last year.

CellaVision AB Receives Its First Major Order for the Veterinary Market

CellaVision AB has received its first major order to a veterinary laboratory chain in the US market. The order supplies equipment to multiple laboratories and will be delivered before the end of this year. As the veterinary market is still relatively small and is characterized by few large customers, an order of this size should be seen as a one-time event. The order has a value of about SEK 10 million. Additional sales to the customer's remaining laboratories depend on certain evaluations that will be conducted in 2015. With a positive outcome, the majority of the chain's laboratories may be equipped with CellaVision® DM9600 Vet and CellaVision®1200 Vet. Since 2012, CellaVision has developed systems specifically for the veterinary market. Since then, the company has entered the US market which is characterized by a few large laboratory chains which together have about a hundred laboratories having significant sample volumes, primarily from dogs and cats.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEVI:SS kr53.50 SEK +1.50

CEVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.15 USD +0.46
Siemens AG €98.42 EUR +1.52
Sysmex Corp ¥6,530 JPY -110.00
View Industry Companies
 

Industry Analysis

CEVI

Industry Average

Valuation CEVI Industry Range
Price/Earnings 36.6x
Price/Sales 5.3x
Price/Book 7.6x
Price/Cash Flow 36.6x
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLAVISION AB, please visit www.cellavision.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.